Anjali S Advani MD

Hematologic Oncology

Director, Inpatient Leukemia Unit, Cleveland Clinic Taussig Cancer Institute Professor of Medicine, Cleveland Clinic Lerner College of Medicine

Join to view full profile

9500 Euclid AveCleveland, OH 44195
Phone+1 800-223-2273
Fax+1 216-986-1191

Dr. Advani is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Advani's full profile Already have an account?

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 1999 - 2002
Duke University HospitalResidency, Internal Medicine, 1996 - 1999
Duke University School of MedicineClass of 1996

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

OH State Medical License 2002 - 2027
NC State Medical License 1997 - 2003
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012-2017
CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2012-2017

Clinical Trials

Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia
COMPLETED
PHASE1
Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia
TERMINATED
PHASE2
S0530 Cytarabine and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
COMPLETED
PHASE2

Publications & Presentations

PubMed

Genomic drivers of leukemia and blinatumomab response in adult acute lymphoblastic leukemia - the ECOG-ACRIN E1910 study.
Xiaoming Zhong, Kathryn G Roberts, Huimei Wei, Zhuoxin Sun, Lindsey E Montefiori
Blood. 2026-10-05
The Prognostic Utility of Normal Karyotype Fraction in Acute Myeloid Leukemia.
Ameed Bawwab, Emily C Zabor, Lana Khatib, Moath Albliwi, John Hanna
Clinical Lymphoma, Myeloma & Leukemia. 2026-10-01
2 citations
Ziftomenib with venetoclax and azacitidine for relapsed/refractory NPM1-mutated acute myeloid leukemia.
Eunice S Wang, Harry Erba, Amer M Zeidan, Gail J Roboz, Jessica K Altman
Blood. 2026-10-01

Journal Articles

A Phase 1 Trial of Vadastuximab Talirine Combined with Hypomethylating Agents in Patients with CD33 Positive AML
Eytan M Stein, Anand Jillella, Anthony S Stein, Amir T Fathi, Roland B Walter, Jeffrey E Lancet, Tibor J Kovacsovics, Anjali S Advani, Phoenix A Ho, Dale Bixby, Blood

Abstracts/Posters

Are Racial Disparities in Acute Myeloid Leukemia (AML) Clinical Trial Enrollment Associated with Comorbidities and/or Organ Dysfunction?
Anjali S. Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with R...
Anjali S. Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
ANKRD26 Coding Variants Presenting with Giant Platelets and a Predisposition to Myeloid Neoplasia
Anjali S. Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Acute Lymphoblastic Leukemia: Aiming High to Keep MRD Low, or Even Better, Negative
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Differences in Genomic Patterns between African Americans and Whites with Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Ponatinib Linked with Better Outcomes Than Imatinib in Philadelphia Chromosome-Positive ALLMarch 17th, 2023
New Treatment Combination Without Chemotherapy Is Effective in PH+ Acute Lymphoblastic LeukemiaDecember 13th, 2021
Addition of Ixazomib to MEC Chemotherapy Promising in R/R AMLAugust 30th, 2019